JPWO2021045202A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021045202A5 JPWO2021045202A5 JP2021544056A JP2021544056A JPWO2021045202A5 JP WO2021045202 A5 JPWO2021045202 A5 JP WO2021045202A5 JP 2021544056 A JP2021544056 A JP 2021544056A JP 2021544056 A JP2021544056 A JP 2021544056A JP WO2021045202 A5 JPWO2021045202 A5 JP WO2021045202A5
- Authority
- JP
- Japan
- Prior art keywords
- polysulfide
- cancer
- tissue
- agent
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 229920001021 polysulfide Polymers 0.000 claims 11
- 239000005077 polysulfide Substances 0.000 claims 11
- 150000008117 polysulfides Polymers 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 229940041181 antineoplastic drug Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000001069 Raman spectroscopy Methods 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Claims (10)
- 対象組織中のポリスルフィドのレベルを測定する工程を含む、前記対象組織中におけるがん細胞の抗がん剤耐性を判別するためのデータ取得方法であって、
前記抗がん剤が、ポリスルフィドと反応性のある抗がん剤である、方法。 - 前記測定が、抗がん剤の投与前に測定するものである、請求項１に記載の方法。
- 前記測定する工程が、ラマン分光法によってポリスルフィドに特異的なピークを検出することによる工程である、請求項１又は２に記載の方法。
- 前記特異的なピークが、がん組織におけるラマン分光法を行った場合、ラマンシフト４８０±１０ｃｍ－１の位置に現れるピークである、請求項３に記載の方法。
- 前記抗がん剤が、シスプラチン又はゲムシタビンである、請求項１～４の何れか一項に記載の方法。
- 前記対象組織が、卵巣がん組織又は膵臓がん組織である、請求項１～５の何れか一項に記載の方法。
- 前記卵巣がん組織が、卵巣明細胞がん組織である請求項６に記載の方法。
- ポリスルフィドのレベルを指標として、対象組織中のポリスルフィドのレベルが対照組織中のポリスルフィドのレベルよりも高いときに、前記対象組織中におけるがん細胞が抗がん剤に対する耐性を有することを示す、がん細胞の抗がん剤に対する耐性についての予測データの取得方法であって、
前記抗がん剤が、ポリスルフィドと反応性のある抗がん剤である、方法。 - がん細胞の抗がん剤耐性を判別するためのマーカーとしてのポリスルフィドの使用であって、
前記抗がん剤が、ポリスルフィドと反応性のある抗がん剤である、使用。 - ポリスルフィドのレベルをラマン分光法により測定するための基板を含む、がん細胞の抗がん剤耐性を判別するためのキットであって、
前記抗がん剤が、ポリスルフィドと反応性のある抗がん剤である、キット。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019162162 | 2019-09-05 | ||
| PCT/JP2020/033640 WO2021045202A1 (ja) | 2019-09-05 | 2020-09-04 | がん細胞の存在及び／又は抗がん剤耐性の判別のためのデータ取得方法及び予測データの取得方法、並びにその判別マーカーの使用及び判別キット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021045202A1 JPWO2021045202A1 (ja) | 2021-03-11 |
| JPWO2021045202A5 true JPWO2021045202A5 (ja) | 2022-06-30 |
Family
ID=74853257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544056A Pending JPWO2021045202A1 (ja) | 2019-09-05 | 2020-09-04 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220365087A1 (ja) |
| EP (1) | EP4026588A4 (ja) |
| JP (1) | JPWO2021045202A1 (ja) |
| CN (1) | CN114341626B (ja) |
| WO (1) | WO2021045202A1 (ja) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010107960A1 (en) * | 2009-03-17 | 2010-09-23 | Brody Jonathan R | Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels |
| WO2013072465A1 (en) * | 2011-11-17 | 2013-05-23 | Institut Curie | Dual gene expression signature to predict clinical outcome and therapeutic response of a patient affected with a cancer |
| CN108872187B (zh) * | 2018-03-30 | 2021-03-05 | 詹晓凯 | 一种利用拉曼成像技术检测耐药性的方法及其应用 |
-
2020
- 2020-09-04 WO PCT/JP2020/033640 patent/WO2021045202A1/ja active Search and Examination
- 2020-09-04 CN CN202080062594.2A patent/CN114341626B/zh active Active
- 2020-09-04 US US17/640,516 patent/US20220365087A1/en active Pending
- 2020-09-04 EP EP20861322.4A patent/EP4026588A4/en active Pending
- 2020-09-04 JP JP2021544056A patent/JPWO2021045202A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jomrich et al. | Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection | |
| Gondo et al. | Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy | |
| Cristofanilli et al. | Circulating tumor DNA to monitor metastatic breast cancer. | |
| Wu et al. | Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies | |
| Lee et al. | Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies | |
| Sève et al. | The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer | |
| EP1956335A3 (en) | Velocity measurement using manetoresistive sensors | |
| CN103422853A (zh) | 一种确定地层含水饱和度的方法及装置 | |
| MX2012007689A (es) | Metodo de agrupamiento mejorado para imagenes de pozo de sondeo. | |
| Higgins et al. | Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma | |
| Kim et al. | Voltammetric studies of topotecan transfer across liquid/liquid interfaces and sensing applications | |
| Moschini et al. | Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy | |
| WO2015041972A8 (en) | Automatic pin adjustment indicator for archery sights | |
| Jia et al. | An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer | |
| JPWO2021045202A5 (ja) | ||
| Imai et al. | Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer | |
| WO2015091575A3 (en) | Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer | |
| Lu et al. | Evaluation of the accumulation of disulfiram and its copper complex in A549 cells using mass spectrometry | |
| Abbaspour et al. | Carbon composite–PVC based membrane coated platinum electrode for chromium determination | |
| JP2015524055A5 (ja) | ||
| Melichar | Biomarkers in the management of lung cancer: changing the practice of thoracic oncology | |
| WO2011153345A3 (en) | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients | |
| He et al. | A survey of survival outcomes for targeted cancer drugs approved by the US food and drug administration | |
| WO2008133012A1 (ja) | 着衣のままでの血圧を測定できる血圧測定装置 | |
| CN204085420U (zh) | 一种精密水平倾角测量仪 |